Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D020137:Base Pair Mismatch; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D002648:Child; D002675:Child, Preschool; D004260:DNA Repair; D003606:Dacarbazine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D000077146:Irinotecan; D008297:Male; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000378:metabolism; D010641:Phenotype; D000077204:Temozolomide; D013997:Time Factors
D000077146:Irinotecan; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D002166:Camptothecin; D000077204:Temozolomide